Comprehensive multi‐omics analysis of resectable locally advanced gastric cancer: Assessing response to neoadjuvant camrelizumab and chemotherapy in a single‐center, open‐label, single‐arm phase II trialYuzhou Zhao, Ying Liu, Jinbang Wang et al.|Clinical and Translational Medicine|2024Cited by 22
Rechallenge of immune checkpoint inhibitors in advanced non‐small cell lung cancerQian Miao, Zhijie Wang, Qian Chu et al.|Thoracic Cancer|2024Cited by 19
Clinical definition of secondary resistance to immunotherapy in non‐small cell lung cancerDingzhi Huang, Qian Miao, Qian Chu et al.|Thoracic Cancer|2023Cited by 5
Association of genomic characterization with clinical benefits of anti-PD-1 antibody combined with FOLFOX as neoadjuvant therapy on locally advanced gastric or gastroesophageal junction adenocarcinoma.Ying Liu, Danyang Li, Guangsen Han et al.|Journal of Clinical Oncology|2021Cited by 0